featured
De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
Lancet Oncol 2024 Nov 26;[EPub Ahead of Print], XC Chen, DC Jiao, JH Qiao, CZ Wang, XF Sun, ZD Lu, LF Li, CJ Zhang, M Yan, Y Wei, B Chen, YQ Feng, M Deng, MD Ma, JK Plichta, YW He, ZZ LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.